Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

Published:2018-05-15 Issue:3 Volume:12 Page:324-330
ISSN:1976-2283
Container-title:Gut and Liver
language:en
Short-container-title:Gut and Liver

Author:

Lee Hye Won¹²³,Oh Se Rim¹,Kim Dong Yun¹,Jeong Yechan¹⁴,Kim Seungtaek¹²³,Kim Beom Kyung¹²³,Kim Seung Up¹²³,Kim Do Young¹²³,Ahn Sang Hoon¹²³,Han Kwang-Hyub¹²³,Park Jun Yong¹²³

Affiliation:

1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

2. Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea

3. Yonsei Liver Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

4. Brain Korea 21 PLUS Project for Medical Science College of Medicine, Seoul, Korea

Funder

Korea Health Industry Development Institute(KHIDI)

Ministry of Health and Welfare(Ministry of Health, Welfare and Family Affairs)

Publisher

The Editorial Office of Gut and Liver

Subject

Gastroenterology,Hepatology

Link

http://pdf.medrang.co.kr/GNL/2018/012/ekjg012-03-16.pdf

Reference37 articles.

1. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients

2. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region

3. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus

4. Prognosis of chronic hepatitis c: Results of a large, prospective cohort study

5. Global epidemiology and genotype distribution of the hepatitis C virus infection

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials;Gut and Liver;2021-11-15

2. Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care;Clinical and Molecular Hepatology;2021-01-01

3. Daclatasvir and Sofosbuvir Mitigate Hepatic Fibrosis Through Downregulation of TNF-α / NF-κB Signaling Pathway;Current Molecular Pharmacology;2020-11-02

4. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals;World Journal of Gastroenterology;2020-06-07

5. Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test;Journal of Medical Virology;2019-09-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3